Search
EHA-ASH TRTH Joint Oversight Committee
Current committee members
Janis Abkowitz
David Bodine
Chiara Bonini
Ruud Delwel
Mary Dinauer
Terry Fry
Jessica Okosun
Kostas Stamatopoulos
AimTo develop, in collaboration with ASH, translational researchers in Europe and beyond by running the TRTH program while maintaining quality of the program elements by choosing and guiding the faculty…
GAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
EHA Taskforce on Diversity, Equity, and Inclusion
The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:
Initiating and implementing activities to empower underrepresented groups.
Standards for functional precision medicine project update, December 2023
A project update from Prof Philipp Staber. We're confident that we'll successfully finish our SWG-initiated small research project, ‘standards for functional precision medicine (StFPM),’ within the next six months.
Read moreHighlights from the SWG
SWG session at EHA2023The EHA2023 Congress was held in Frankfurt, Germany, in June 2023. As part of this event, the SWG held a session on Saturday, June 10, 2023. Title‘Stem cells: Clonal and mutational dynamics of hematopoietic stem cells.
Read moreHow to apply
The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)
Notification
November 2024
Questions: training@ehaweb. orgDownload the Signature letter template.
EU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »